SCHEMBL19357261

SCHEMBL19357261

COc1cnc(-c2nn(CC3CCC3)c3ccccc23)nc1Nc1ccncc1C(N)=O

nearest known ligand 0.72

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
BUB1 O43683 20/20 0.72
SLC28A1 O00337 1/20 0.52
STK10 O94804 1/20 0.52
HTR1A P08908 1/20 0.52
DDR1 Q08345 1/20 0.52
CDC42BPG Q6DT37 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19357181 0.98 BUB1 (0.72) BUB1SLC28A1STK10HTR1ADDR1
SCHEMBL19357272 0.98 BUB1 (0.71) BUB1SLC28A1STK10HTR1ADDR1
SCHEMBL19357220 0.98 BUB1 (0.71) BUB1SLC28A1STK10HTR1ADDR1
SCHEMBL19357139 0.97 BUB1 (0.74) BUB1SLC28A1STK10HTR1ADDR1
SCHEMBL19357303 0.92 BUB1 (0.71) BUB1SLC28A1STK10HTR1ADDR1
SCHEMBL19357270 0.91 BUB1 (0.69) BUB1
SCHEMBL19357234 0.89 BUB1 (0.71) BUB1SLC28A1STK10HTR1ADDR1
SCHEMBL19357271 0.87 BUB1 (0.66) BUB1SLC28A1STK10HTR1ADDR1
SCHEMBL19357213 0.86 BUB1 (0.58) BUB1SLC28A1STK10HTR1ADDR1
SCHEMBL19357222 0.86 BUB1 (0.61) BUB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017157991-A1 1-ALKYL-PYRAZOLES AND -INDAZOLES AS BUB1 INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-09-21 WO claimed
WO-2017157991-A1 1-ALKYL-PYRAZOLES AND -INDAZOLES AS BUB1 INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-09-21 WO disclosed
WO-2017157991-A1 1-ALKYL-PYRAZOLES AND -INDAZOLES AS BUB1 INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-09-21 WO disclosed